Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 10/20 | 0.45 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ABL2 | P42684 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25047434 | 0.89 | PRMT5 (0.43) | PRMT5WDR77MEN1ADK | |
| SCHEMBL25047449 | 0.88 | RIPK2 (0.42) | PRMT5WDR77MEN1RIPK2ADK | |
| SCHEMBL25046606 | 0.86 | RIPK2 (0.44) | PRMT5WDR77MEN1RIPK2 | |
| SCHEMBL25049275 | 0.84 | PRMT5 (0.45) | PRMT5WDR77MEN1ADK | |
| SCHEMBL25047466 | 0.84 | PRMT5 (0.42) | PRMT5WDR77MEN1 | |
| SCHEMBL25047906 | 0.84 | PRMT5 (0.43) | PRMT5WDR77MEN1 | |
| SCHEMBL25048170 | 0.83 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL25046760 | 0.82 | PRMT5 (0.40) | PRMT5WDR77MEN1ADK | |
| SCHEMBL25047463 | 0.81 | PRMT5 (0.40) | PRMT5WDR77MEN1ADK | |
| SCHEMBL25047638 | 0.80 | PRMT5 (0.42) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |